| Bioactivity | BAY-9835 is a potent and orally active ADAMTS7 and ADAMTS12 antagonist with IC50s of 6 nM and 30 nM, respectively. BAY-9835 is very selective against a range of off-targets and metalloproteases. BAY-9835 can be used for the atherogenesis research[1]. |
| Target | IC50: 6 nM (ADAMTS7) and 30 nM (ADAMTS12) |
| Formula | C22H16F5N5O3 |
| Molar Mass | 493.39 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Daniel Meibom, et al. BAY-9835: Discovery of the First Orally Bioavailable ADAMTS7 Inhibitor. J Med Chem. 2024 Feb 22;67(4):2907-2940. |